Silence Therapeutics plc (LON:SLN) had its price target boosted by Canaccord Genuity from GBX 233 ($3.04) to GBX 249 ($3.25) in a research report report published on Tuesday. They currently have a buy rating on the stock.
Silence Therapeutics plc (LON:SLN) opened at 122.50 on Tuesday. The firm’s market capitalization is GBX 85.51 million. Silence Therapeutics plc has a 52-week low of GBX 96.62 and a 52-week high of GBX 235.25. The company’s 50-day moving average is GBX 114.67 and its 200-day moving average is GBX 116.50.
About Silence Therapeutics plc
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.